 | | Vol. 10.15 – 20 April, 2022 |
| |
|
|
| Scientists investigated the extent of protection afforded by previous exposure to SARS-CoV-2 on subsequent COVID-19 infection, as well as the efficacy, safety, and reactogenicity of SCB-2019 in participants who were enrolled in Clover’s COVID-19 vaccine trial.
[Lancet Infectious Diseases] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| To address future zoonotic outbreaks due to related viruses in the sarbecovirus subgenus, investigators identified a human monoclonal antibody, 10-40, that neutralized or bound all sarbecoviruses tested in vitro and protected against SARS-CoV-2 and SARS-CoV in vivo.
[Science Translational Medicine] |
|
|
|
| Researchers established a lung and macrophage co-culture system derived from human pluripotent stem cells, modeling the host-pathogen interaction in SARS-CoV-2 infection.
[Nature Communications] |
|
|
|
| The authors demonstrated that BND cells from SARS-CoV-2 severely infected individuals were significantly activated, displayed reduced inhibitory receptor expression, and restored B cell receptor signaling, indicative of a breach in anergy during viral infection, supported by increased levels of autoreactive antibodies.
[Journal of Experimental Medicine] |
|
|
|
| To recognize the significance of adaptive spike protein changes, scientists compared variant SARS-CoV-2 virus particles in several assays reflecting authentic virus-cell entry.
[Cell Reports] |
|
|
|
| Researchers found that cell fusion caused by the SARS-CoV-2 spike protein induced a type I interferon response and that that cell fusion damaged nuclei and resulted in the formation of micronuclei that were sensed by the cytosolic DNA sensor cGAS and led to the activation of its downstream effector STING.
[Science Signaling] |
|
|
|
| A cohort of convalescent healthcare workers was recruited and their immune responses were studied over a period of three to nine months following the onset of symptoms.
[Frontiers in Immunology] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Scientists showed here that NK cell depletion enhanced antigen-specific T cell responses to chimp adenoviral vector vaccination in a mouse model of chronic hepatitis B virus infection.
[Science Translational Medicine] |
|
|
|
| The authors present the pantothenamide MMV693183 as a first-in-class acetyl-CoA synthetase inhibitor to enter preclinical development and demonstrated attractive drug-like properties and in vivo efficacy in a humanized mouse model of Plasmodium falciparum infection.
[Nature Communications] |
|
|
|
| Investigators showed that HIV-1 cell-to-cell spread permited efficient, productive infection of resting memory T cells without prior activation.
[Cell Reports] |
|
|
|
| Scientists examined viral gene expression dynamics during the establishment of both productive and latent human cytomegalovirus (HCMV) infections.
[Cell Reports] |
|
|
|
| Researchers found that human nasal commensal Staphylococcus epidermidis promoted protease–protease inhibitor balance in favor of the host and prevented influenza A virus replication in the nasal mucosa and lungs.
[NPJ Biofilms and Microbiomes] |
|
|
|
| The authors showed that enterovirus 71 (EV71) engagement with intracellular receptor TLR9 elicited IL-12p40-iNOS signaling causing encephalitis in mice. They identified IL-12p40 to be the only prominent cytokine-induced at the early infection stage in the brainstem of mice subjected to a lethal dose of EV71.
[Cell Death & Disease] |
|
|
|
| Researchers generated a virus-like particle (VLP) vaccine bearing the hemagglutinin of H1N1 A/California/07/09 that was unable to bind to its α(2,6)-linked sialic acid receptor and compared its immunogenicity and efficacy to a wild-type H1-VLP in mice.
[NPJ Vaccines] |
|
|
|
|
| The authors present their work identifying SARS-CoV-2 epitopes to quantify T cell responses and review how T cells may help protect against severe disease.
[Clinical Infectious Diseases] |
|
|
|
| Scientists review the predictive and functional significance of recently suggested viral and host biomarkers of time to viral rebound and post-treatment control following ART interruption.
[Current HIV/AIDS Reports] |
|
|
|
|
| ImmVira recently announced that they have reached an agreement with Roche to establish a clinical research partnership to conduct clinical studies in the US on the combination therapy of ImmVira’s MVR-T3011 IT and Roche’s MEK inhibitor cobimetinib, to evaluate the safety and efficacy of this combo strategy.
[ImmVira (Cision US, Inc.)] |
|
|
|
| Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced initial results from the Phase I/II clinical trial of its COVID-Influenza Combination Vaccine.
[Novavax, Inc.] |
|
|
|
| In South Africa, a network of researchers is studying whether lineages BA.4 and BA.5 escape immunity from COVID-19 vaccines and previous infections.
[Nature] |
|
|
|
|
| June 1 – 4, 2022
Breckenridge, Colorado, United States |
|
|
|
|
|
| | Uppsala University – Uppsala, Sweden |
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | Francis Crick Institute – London, England, United Kingdom |
|
|
|
| | Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
| | University of Kentucky – Lexington, Kentucky, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
